https://seekingalpha.com/article/4679198-biogen-inc-biib-stifel-2024-virtual-cns-days-transcript?source=feed_sector_transcripts
Mar 19, 2024 - Biogen Inc. (NASDAQ:NASDAQ:BIIB) Stifel 2024 Virtual CNS Days Conference March 19, 2024 10:00 AM ETCompany ParticipantsPriya Singhal - Head of Development...
0
sa:4505347782695792828
0
https://www.fool.com/earnings/call-transcripts/2024/02/13/biogen-biib-q4-2023-earnings-call-transcript/?source=iedfolrf0000001
Feb 13, 2024 - BIIB earnings call for the period ending December 31, 2023.
0
fool:-2247995043838259553
0
https://www.fool.com/earnings/call-transcripts/2024/04/24/biogen-biib-q1-2024-earnings-call-transcript/?source=iedfolrf0000001
Apr 24, 2024 - BIIB earnings call for the period ending March 31, 2024.
0
fool:128492039449573275
0
https://www.zacks.com/stock/news/2199443/biogen-s-biib-rare-disease-drug-skyclarys-gets-chmp-nod-in-eu?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2199443
Dec 18, 2023 - Biogen (BIIB) gets positive CHMP opinion recommending marketing authorization to Skyclarys in the EU for the treatment of Friedreich's ataxia in patients aged 16 years and older.
zc:2911842454942124004
0
https://www.zacks.com/stock/news/2214591/biogen-inc-biib-rises-higher-than-market-key-facts?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v1-2214591
Jan 23, 2024 - Biogen Inc. (BIIB) closed the most recent trading day at $251.68, moving +1.36% from the previous trading session.
zc:-5469850038890312299
0
https://www.zacks.com/stock/news/2217370/will-biogen-inc-biib-beat-estimates-again-in-its-next-earnings-report?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_7-2217370
Jan 29, 2024 - Biogen Inc. (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
zc:-5012130644135588207
0
https://www.zacks.com/stock/news/2223511/can-biogen-biib-keep-the-beat-streak-alive-in-q4-earnings?cid=CS-ZC-FT-analyst_blog|earnings_preview-2223511
Feb 08, 2024 - Biogen's (BIIB) sales in the fourth quarter are likely to have been hurt by lower sales of its multiple sclerosis drugs, while sales of Spinraza are likely to have risen.
zc:6972093638616546294
0
https://www.zacks.com/stock/news/2226390/where-are-biotech-etfs-headed-after-q4-earnings?cid=CS-ZC-FT-etf_news_and_commentary-2226390
Feb 14, 2024 - Look into how Biotech ETFs performed after Q4 earnings.
zc:6928781431631922699
0
https://www.zacks.com/stock/news/2227293/ionis-ions-olezarsen-gets-fda-s-orphan-tag-for-rare-disease?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2227293
Feb 16, 2024 - FDA grants orphan drug status to Ionis' (IONS) olezarsen for treating familial chylomicronemia syndrome (FCS). An NDA for olezarsen is expected to be filed this year.
zc:-4389715286765519151
0
https://www.zacks.com/stock/news/2239569/biogen-inc-biib-stock-falls-amid-market-uptick-what-investors-need-to-know?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v1-2239569
Mar 12, 2024 - Biogen Inc. (BIIB) concluded the recent trading session at $227.36, signifying a -1.18% move from its prior day's close.
zc:-5448833693767717157
0